OLP-1002

N/A

Report date: 2026/05/07 20:00:36

Base Information

Drug NameOLP-1002

Drug Alias NameOLP-1002

ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Peptide nucleic acidsSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense

Mechanisms of ActionSodium channel protein type IX alpha subunit blockers

TargetsSodium channel protein type IX alpha subunit

Therapy Area/IndicationsOsteoarthritis

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryAustralia

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesOlipass Co

China Registration ClassN/A

Develop Information

Active CompaniesOlipass Co

Inactive CompaniesOliPass Australia Pty Ltd

Active IndicationsOsteoarthritis

Inactive IndicationsN/A

Other Information

ATC CodeN/A